This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Al-Batran, S.-E. Articles by Jaeger, E. Search for Related Content PubMed PubMed Citation Articles by Al-Batran, S.-E. Articles by Jaeger, E. Social Bookmarking                            What's this?

Phase II Trial of Biweekly Infusional Fluorouracil, Folinic Acid, and Oxaliplatin in Patients With Advanced Gastric Cancer

From the Krankenhaus Nordwest and Johann-Wolfgang-Goethe Universitätsklinik, Frankfurt; Universitätsklinikum Hamburg-Eppendorf, Hamburg; Onkologische Praxis, Jena; Onkologische Praxis, Bad Soden; Klinikum Darmstadt, Darmstadt; Internistisch-Onkologische Praxis, Eltville, Germany; Universitätsspital Zürich, Zürich, Switzerland

Address reprint requests to E. Jaeger, MD, Krankenhaus Nordwest, 60488 Frankfurt am Main, Germany; e-mail: EJ200161{at}aol.com

PURPOSE: To evaluate the toxicity and activity of infusional fluorouracil (FU), folinic acid (FA), and oxaliplatin, administered every 2 weeks in patients with metastatic gastric cancer.

PATIENTS AND METHODS: Forty-one previously untreated patients with measurable adenocarcinoma of the stomach were eligible for the study. Patients received FU 2.6 g/m² (24-hour continuous infusion), FA 500 mg/m² (2-hour intravenous infusion), and oxaliplatin 85 mg/m² (2-hour intravenous infusion) every 2 weeks for 6 weeks. Treatment was continued until progression of disease was observed.

RESULTS: All patients were assessable for toxicity and 37 of 41 patients were assessable for response. Patient characteristics were: sex (male, 28; female,13), median age 60 years (range, 20 to 77 years), and median Eastern Cooperative Oncology Group performance status of 1. Response was evaluated every 6 weeks. Of 37 assessable patients, one complete and 15 partial remissions were observed (overall response rate, 43%). Stable disease was observed in 12 patients (32%) and progressive disease in nine patients (24%). The median overall survival was 9.6 months. WHO grade 3 or 4 hematologic toxicities included neutropenia in two patients (4.9%) and thrombocytopenia in one patient (2.4%). Other WHO grade 3 or 4 toxicities included diarrhea in three patients (7.3%) and vomiting in two patients (4.9%). There were no cases of grade 3 peripheral neuropathy and no treatment-related deaths.

CONCLUSION: Biweekly fluorouracil, folinic acid, and oxaliplatin is active and well-tolerated in patients with advanced gastric cancer. Response rates, time to progression, and overall survival were comparable to those achieved with other combination chemotherapy regimens, including FOLFOX6, with significantly less toxicity.

Submitted July 7, 2003; accepted December 10, 2003.

Presented in part at the 2003 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 3, 2003.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. Goekkurt, S.-E. Al-Batran, J. T. Hartmann, U. Mogck, G. Schuch, M. Kramer, E. Jaeger, C. Bokemeyer, G. Ehninger, and J. Stoehlmacher Pharmacogenetic Analyses of a Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma With Fluorouracil and Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie J. Clin. Oncol., June 10, 2009; 27(17): 2863 - 2873. [Abstract] [Full Text] [PDF]

				L. Celio, C. N. Sternberg, R. Labianca, I. La Torre, V. Amoroso, C. Barone, G. Pinotti, S. Cascinu, F. Di Costanzo, G. L. Cetto, et al. Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study Ann. Onc., June 1, 2009; 20(6): 1062 - 1067. [Abstract] [Full Text] [PDF]

				E. Goekkurt, S.-E. Al-Batran, U. Mogck, C. Pauligk, J. T. Hartmann, M. Kramer, E. Jaeger, G. Ehninger, and J. Stoehlmacher Pharmacogenetic analyses of hematotoxicity in advanced gastric cancer patients receiving biweekly fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Ann. Onc., March 1, 2009; 20(3): 481 - 485. [Abstract] [Full Text] [PDF]

				S.-E. Al-Batran, J. T. Hartmann, R. Hofheinz, N. Homann, V. Rethwisch, S. Probst, J. Stoehlmacher, M. R. Clemens, R. Mahlberg, M. Fritz, et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Ann. Onc., November 1, 2008; 19(11): 1882 - 1887. [Abstract] [Full Text] [PDF]

				S.-E. Al-Batran, J. T. Hartmann, S. Probst, H. Schmalenberg, S. Hollerbach, R. Hofheinz, V. Rethwisch, G. Seipelt, N. Homann, G. Wilhelm, et al. Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie J. Clin. Oncol., March 20, 2008; 26(9): 1435 - 1442. [Abstract] [Full Text] [PDF]

				W. P. Ceelen, M. Peeters, P. Houtmeyers, C. Breusegem, F. De Somer, and P. Pattyn Safety and Efficacy of Hyperthermic Intraperitoneal Chemoperfusion with High-Dose Oxaliplatin in Patients with Peritoneal Carcinomatosis Ann. Surg. Oncol., February 1, 2008; 15(2): 535 - 541. [Abstract] [Full Text] [PDF]

				D. Richards, D. McCollum, L. Wilfong, M. Sborov, K. A. Boehm, F. Zhan, and L. Asmar Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction Ann. Onc., January 1, 2008; 19(1): 104 - 108. [Abstract] [Full Text] [PDF]

				M. P. Lutz, H. Wilke, D.J. T. Wagener, U. Vanhoefer, K. Jeziorski, S. Hegewisch-Becker, L. Balleisen, E. Joossens, R. L. Jansen, M. Debois, et al. Weekly Infusional High-Dose Fluorouracil (HD-FU), HD-FU Plus Folinic Acid (HD-FU/FA), or HD-FU/FA Plus Biweekly Cisplatin in Advanced Gastric Cancer: Randomized Phase II Trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie J. Clin. Oncol., June 20, 2007; 25(18): 2580 - 2585. [Abstract] [Full Text] [PDF]

				J Lee, W. Kang, J. Kwon, S. Oh, H. Lee, H. Kim, B. Park, H. Lim, M. Han, J. Park, et al. Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma Ann. Onc., January 1, 2007; 18(1): 88 - 92. [Abstract] [Full Text] [PDF]

				K. Yoshida, M. Ninomiya, N. Takakura, N. Hirabayashi, W. Takiyama, Y. Sato, S. Todo, M. Terashima, M. Gotoh, J. Sakamoto, et al. Phase II Study of Docetaxel and S-1 Combination Therapy for Advanced or Recurrent Gastric Cancer. Clin. Cancer Res., June 1, 2006; 12(11): 3402 - 3407. [Abstract] [Full Text] [PDF]

				L. Lim, M. Michael, G. B. Mann, and T. Leong Adjuvant Therapy in Gastric Cancer J. Clin. Oncol., September 1, 2005; 23(25): 6220 - 6232. [Abstract] [Full Text] [PDF]

				L. Di Lauro, F. Belli, M. G. Arena, S. Carpano, G. Paoletti, D. Giannarelli, and M. Lopez Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer Ann. Onc., September 1, 2005; 16(9): 1498 - 1502. [Abstract] [Full Text] [PDF]

				P. C. Thuss-Patience, A. Kretzschmar, M. Repp, D. Kingreen, D. Hennesser, S. Micheel, D. Pink, C. Scholz, B. Dorken, and P. Reichardt Docetaxel and Continuous-Infusion Fluorouracil Versus Epirubicin, Cisplatin, and Fluorouracil for Advanced Gastric Adenocarcinoma: A Randomized Phase II Study J. Clin. Oncol., January 20, 2005; 23(3): 494 - 501. [Abstract] [Full Text] [PDF]